Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

West Orange Endocrinology

Neither a doctor nor a teaching hospital

Research payments

$2,047,666

54 payments

Through program year 2025, West Orange Endocrinology is reported as receiving $2,047,666 in research payments, across 54 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $637,577 6
2024 Research $155,491 6
2023 Research $492,212 2
2022 Research $195,929 4
2021 Research $417,181 32
2020 Research $149,276 4

Breakdown

Who paid Research payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $1,824,107 20 payments
  2. AbbVie, Inc. $215,212 30 payments
  3. Lexicon Pharmaceuticals, Inc. $8,319 2 payments
  4. Novo Nordisk AS $28 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $689,589 8 payments
  2. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $451,744 6 payments
  3. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $438,803 2 payments
  4. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $178,457 2 payments
  5. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $136,891 15 payments
  6. 24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy $72,537 14 payments
  7. a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure $57,015 1 payment
  8. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $8,500 1 payment
  9. Efc-15166 $6,719 1 payment
  10. A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism $5,784 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record